Gao Yang, Zhou Yang, He Xiaolin, Lin Hongwei, Fang Keying, Hou Qijun, Wang Huafang, Zhang Honghao, Zhang Yixi, Li Yuhua
Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Department of Anesthesiology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2518634. doi: 10.1080/21645515.2025.2518634. Epub 2025 Jun 17.
In recent years, the integration of nanoparticles with chimeric antigen receptor T-cell (CAR-T) therapy has advanced rapidly, garnering considerable attention from both academic and industrial sectors. However, a comprehensive analysis of key trends and emerging frontiers in this interdisciplinary field remains lacking. To address this gap, we conducted a bibliometric analysis of 515 publications indexed in the Web of Science Core Collection from 2013 to 2024. Using VOSviewer, CiteSpace, and R-bibliometrix, we analyzed publication trends, influential journals, national and institutional contributions, leading authors, and high-impact references. Keyword co-occurrence analyses were performed in VOSviewer, applying a minimum occurrence threshold of five. Citation bursts and clustering analyses of references and keywords were conducted using CiteSpace with default detection settings. Our analysis revealed major research hotspots, especially the optimization of CAR-T cell manufacturing processes and strategies to overcome barriers within the immunosuppressive tumor microenvironment. Looking forward, research is expected to focus increasingly on nanotechnologies such as lipid nanoparticles, precision cell tracking, and siRNA delivery platforms. These innovations hold substantial promise for enhancing the therapeutic efficacy of CAR-T therapies, particularly in the treatment of solid tumors, where conventional approaches remain inadequate. By identifying emerging directions and influential research trends, our analysis highlights the dynamic synergy between nanoparticles and CAR-T therapies, helping to fuel groundbreaking advances in tumor immunotherapy. This study provides data-driven insights that inform clinical trial design, foster interdisciplinary collaboration, and demonstrate the field's strong potential to transform future cancer treatment paradigms.
近年来,纳米颗粒与嵌合抗原受体T细胞(CAR-T)疗法的整合发展迅速,引起了学术界和工业界的广泛关注。然而,对这一跨学科领域的关键趋势和新兴前沿的全面分析仍然缺乏。为了填补这一空白,我们对2013年至2024年Web of Science核心合集中索引的515篇出版物进行了文献计量分析。我们使用VOSviewer、CiteSpace和R-bibliometrix分析了出版趋势、有影响力的期刊、国家和机构的贡献、主要作者以及高影响力参考文献。在VOSviewer中进行关键词共现分析,应用的最小出现阈值为五次。使用CiteSpace并采用默认检测设置对参考文献和关键词进行了引文爆发和聚类分析。我们的分析揭示了主要的研究热点,特别是CAR-T细胞制造工艺的优化以及克服免疫抑制肿瘤微环境中障碍的策略。展望未来,研究预计将越来越多地关注脂质纳米颗粒、精确细胞追踪和siRNA递送平台等纳米技术。这些创新对于提高CAR-T疗法的治疗效果具有巨大潜力,特别是在实体瘤治疗方面,传统方法仍然不足。通过识别新兴方向和有影响力的研究趋势,我们的分析突出了纳米颗粒与CAR-T疗法之间的动态协同作用,有助于推动肿瘤免疫治疗取得突破性进展。本研究提供了数据驱动的见解,为临床试验设计提供参考,促进跨学科合作,并展示了该领域在改变未来癌症治疗模式方面的强大潜力。
Cochrane Database Syst Rev. 2021-9-13
Hematology. 2025-12
Lancet Haematol. 2025-1
Nat Rev Drug Discov. 2024-10
Int J Mol Sci. 2024-6-19
Research (Wash D C). 2024-6-18
Nat Rev Clin Oncol. 2024-7